Other Clinical Trial - Outcome Predictors of a Cognitive Intervention in

Status Completed

Clinical Trial Summary

Cognitive training has been shown to be successful in patients with amnestic mild cognitive impairment (aMCI), a group at high-risk for Alzheimer's disease (AD). Moreover, in a randomized controlled trial, the investigators recently found that aMCI patients receiving a cognitive intervention showed stable hypometabolism in FDG-PET, whereas patients in an active control group showed pronounced hypometabolism on follow-up scans in regions typically affected in AD.

Previous studies indicate that not all patients respond equally well to a cognitive intervention. Identifying factors that predict response to treatment could help selecting patients for a targeted intervention. A potentially important predictor is cognitive reserve defined as premorbid cognitive performance. The hypothesis is that different levels of cognitive reserve (high cognitive reserve vs. low cognitive reserve) have different neurostructural and neurofunctional correlates and influence treatment response in a different way. Moreover, the impact of white matter lesions on treatment effects will be investigated.

The investigator will perform a complex cognitive training program. Forty patients with aMCI (20 with high cognitive reserve, 20 with low cognitive reserve) will be recruited in this study. Since the patients are recruited consecutively, an estimated overall number of 80 will be included and receive the training of whom about 40 will meet the inclusion criteria for our cognitive-reserve-study (high or low cognitive reserve). Data of the whole group will be used to analyze the potential impact of white matter lesions on response to the intervention. Cognitive effects of the intervention will be evaluated by neuropsychological testing. Neurofunctional and neurostructural changes depending on cognitive reserve will be measured using resting state fMRI and diffusion tensor imaging (DTI).

For comparison, a group of 30 aMCI patients will be recruited as an active control group receiving study investigations (neuropsychological testing as well as MRIs), and exercises for self-study at home, not the complex cognitive intervention.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Amnestic Mild Cognitive Impairment
Cognition Disorders
Mild Cognitive Impairment

Clinical Trial Details

NCT number	NCT01525368
Study type	Observational
Source	Ludwig-Maximilians - University of Munich
Contact
Status	Completed
Phase	N/A
Start date	September 2010
Completion date	July 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00785759` - Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers	Phase 2
Recruiting	`NCT05903573` - Training Response Artificial Intelligence Network (TRAIN)	N/A
Completed	`NCT02562989` - [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)	Phase 1
Completed	`NCT02910739` - An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)	Phase 1
Completed	`NCT04185298` - mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment	N/A
Not yet recruiting	`NCT04103463` - Interactive Stepping Exercise on Memory	N/A
Recruiting	`NCT04063956` - COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT	N/A
Terminated	`NCT01953601` - Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)	Phase 3
Recruiting	`NCT06041152` - Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment	Phase 2
Completed	`NCT01962038` - A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment	N/A
Recruiting	`NCT03133052` - CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)	N/A
Not yet recruiting	`NCT05987007` - Sleep Interventions and Neurocognitive Outcomes	N/A
Recruiting	`NCT04240561` - Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia	N/A
Completed	`NCT01767909` - The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)	Phase 2/Phase 3
Terminated	`NCT01072812` - Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment	Phase 1
Completed	`NCT00643266` - Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment	N/A
Active, not recruiting	`NCT04504630` - Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury	N/A
Terminated	`NCT00582855` - Effect of AQW051 in Patients With Memory Impairment	Phase 2
Recruiting	`NCT05446584` - Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Outcome Predictors of a Cognitive Intervention in aMCI — OutPreC MCI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms